PET Imaging of Brain Amyloid Using [11C]MeS-IMPY

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Alzheimer's disease is associated with accumulation in the brain of a protein called amyloid. The purpose of this study is to test the ability of a research drug to measure amyloid in brain using positron emission tomography (PET) and a research drug called [11C]MeS-IMPY.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: National Institute of Mental Health (NIMH)

Criteria

• INCLUSION CRITERIA:

Healthy control subjects aged 18-90 years and AD patients aged 50-90, with history/physical exam, ECG, and laboratory tests.

Informed Consent.

AD Patients: Mini-Mental State Examination (score greater than or equal to 10).

AD Patients: Meet NINCDS-ADRDA criteria for probable AD.

EXCLUSION CRITERIA:

1. Current or prior history of any alcohol or drug abuse.

2. Severe systemic disease based on history and physical exam.

3. Positive result on urine screen for illicit drugs.

4. Laboratory tests with clinically significant abnormalities.

5. Prior participation in other research protocols or clinical care in the last year such that radiation exposure would exceed the annual limits.

6. Pregnancy or breast feeding.

7. Claustrophobia.

8. Presence of ferromagnetic metal in the body or heart pacemaker.

9. History of brain disease other than Alzheimer's disease.

10. Unable to lay on one's back for the PET/MRI scan.